View in EDS

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.

Saved in:
Bibliographic Details
Title: Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Authors: Lerebours, Florence1 (AUTHOR) florence.lerebours@curie.fr, Pulido, Marina2 (AUTHOR), Fourme, Emmanuelle1 (AUTHOR), Debled, Marc3 (AUTHOR), Becette, Véronique4 (AUTHOR), Bonnefoi, Hervé3 (AUTHOR), Rivera, Sofia5 (AUTHOR), MacGrogan, Gaetan3 (AUTHOR), Mouret-Reynier, Marie-Ange6 (AUTHOR), de Lara, Christine Tunon3 (AUTHOR), Pierga, Jean-Yves4 (AUTHOR), Breton-Callu, Christel3 (AUTHOR), Venat-Bouvet, Laurence7 (AUTHOR), Mathoulin-Pélissier, Simone2 (AUTHOR), de la Motte rouge, Thibault8 (AUTHOR), Dalenc, Florence9 (AUTHOR), Sigal, Brigitte4 (AUTHOR), Bachelot, Thomas10 (AUTHOR), Lemonnier, Jérôme11 (AUTHOR), Quenel-Tueux, Nathalie3 (AUTHOR)
Source: British Journal of Cancer. Mar2020, Vol. 122 Issue 6, p759-765. 7p. 1 Diagram, 4 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:00070920
DOI:10.1038/s41416-020-0733-x